TY - JOUR
T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference
AU - Junaid, Vashma
AU - Hinkamp, Colin
AU - Hamid, Arsalan
AU - Abdul Jabbar, Ali Bin
AU - Minhas, Abdul Mannan Khan
AU - Inam, Maha
AU - Khoja, Adeel
AU - Sheikh, Sana
AU - Krittanawong, Chayakrit
AU - Vaughan, Elizabeth M.
AU - Slipczuk, Leandro
AU - Sahebkar, Amirhossein
AU - Kalra, Dinesh K.
AU - Virani, Salim S.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Purpose of Review: To highlight key late-breaking trials and observational studies in cardiovascular disease (CVD) prevention and management presented at the 2025 American College of Cardiology (ACC) Conference. Recent Findings: Key trials presented at the 2025 ACC Conference provide important insights into ASCVD prevention and management. Global data from over two million individuals affirmed that modifying five classic risk factors can prolong life by over a decade. The ALLEPRE trial showed a nurse-led prevention program reduced CV events by 30% post-ACS. A post-hoc analysis of the ESPRIT trial explored intensive blood pressure control in older adults with varying levels of frailty. Several novel RNA-based and oral pharmacologic agents—Solbinsiran, Lepodisiran, and AZD0780—demonstrated significant lipid-lowering efficacy. The SOUL trial demonstrated a 14% MACE reduction with oral semaglutide in patients with high-risk diabetes. WARRIOR found no added benefit of intensive therapy in women with INOCA. A case series from the Race Associated Cardiac Event Registry found that cardiac arrest mortality in long-distance runners has decreased by nearly 50% in the last two decades, highlighting improved emergency responses and defibrillation access. Summary: This year’s ACC findings emphasize global and scalable strategies to reduce cardiovascular risk—ranging from nurse-led care models and intensive blood pressure management to the emergence of novel lipid-lowering agents—marking a shift towards more effective and accessible CVD prevention.
AB - Purpose of Review: To highlight key late-breaking trials and observational studies in cardiovascular disease (CVD) prevention and management presented at the 2025 American College of Cardiology (ACC) Conference. Recent Findings: Key trials presented at the 2025 ACC Conference provide important insights into ASCVD prevention and management. Global data from over two million individuals affirmed that modifying five classic risk factors can prolong life by over a decade. The ALLEPRE trial showed a nurse-led prevention program reduced CV events by 30% post-ACS. A post-hoc analysis of the ESPRIT trial explored intensive blood pressure control in older adults with varying levels of frailty. Several novel RNA-based and oral pharmacologic agents—Solbinsiran, Lepodisiran, and AZD0780—demonstrated significant lipid-lowering efficacy. The SOUL trial demonstrated a 14% MACE reduction with oral semaglutide in patients with high-risk diabetes. WARRIOR found no added benefit of intensive therapy in women with INOCA. A case series from the Race Associated Cardiac Event Registry found that cardiac arrest mortality in long-distance runners has decreased by nearly 50% in the last two decades, highlighting improved emergency responses and defibrillation access. Summary: This year’s ACC findings emphasize global and scalable strategies to reduce cardiovascular risk—ranging from nurse-led care models and intensive blood pressure management to the emergence of novel lipid-lowering agents—marking a shift towards more effective and accessible CVD prevention.
KW - ACC
KW - ASCVD
KW - Lepodisiran
KW - MACE
KW - Oral PCSK9 inhibitor
KW - Semaglutide
UR - https://www.scopus.com/pages/publications/105008584527
U2 - 10.1007/s11883-025-01313-y
DO - 10.1007/s11883-025-01313-y
M3 - Review article
AN - SCOPUS:105008584527
SN - 1523-3804
VL - 27
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 1
M1 - 67
ER -
